Autolus files UK annual report highlighting AUCATZYL launch, pipeline progress, and EU sales delay

Autolus Therapeutics plc

AUCATZYL launched in US (Jan 2025) and UK (Jan 2026) for r/r B-ALL; conditional EU approval but no 2026 sales planned.
Obe-cel paediatric r/r B-ALL Phase 1b showed 95% ORR; Phase 2 enrollment expected complete H1 2027.
Obe-cel advanced to Phase 2 pivotal trial (LUMINA) for lupus nephritis; Phase 1 MS trial dosing started Oct 2025.
Manufacturing site Nucleus in Stevenage, UK; Cardinal Health 105 as US distribution partner.
AGM scheduled for June 29, 2026; ADS holders of record May 27, 2026 eligible to vote.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.